Patient characteristics (n = 103)
| . | n . | % . |
|---|---|---|
| Age, y | ||
| Median (range) | 67 | 20-83 |
| 18-60 | 21 | 20 |
| >60 | 82 | 80 |
| Sex | ||
| Male | 54 | 52 |
| Female | 49 | 48 |
| AML subtype | ||
| MRC-AML | 74 | 72 |
| MDS-AML | 35 | 47 |
| CMML-AML | 9 | 12 |
| t-AML | 27 | 26 |
| Other* | 2 | 2 |
| WBCs, median (range), × 109/L | 3 | 0-156 |
| Hyperleukocytosis | 9 | 9 |
| Cytopenias | 97 | 94 |
| 1 | 25 | 24 |
| 2 | 41 | 40 |
| 3 | 31 | 30 |
| Karyotype | ||
| Complex | 35 | 34 |
| Monosomal | 28 | 27 |
| Prior HMA | 18 | 18 |
| 2017 ELN genetic risk stratification (n = 102) | ||
| Favorable | 2 | 2 |
| Intermediate | 38 | 37 |
| Adverse | 62 | 61 |
| Lindsley’s classifier (n = 80) | ||
| De novo/pan-AML | 21 | 26 |
| Secondary-type mutations AML | 37 | 46 |
| TP53-mutated AML | 22 | 28 |
| . | n . | % . |
|---|---|---|
| Age, y | ||
| Median (range) | 67 | 20-83 |
| 18-60 | 21 | 20 |
| >60 | 82 | 80 |
| Sex | ||
| Male | 54 | 52 |
| Female | 49 | 48 |
| AML subtype | ||
| MRC-AML | 74 | 72 |
| MDS-AML | 35 | 47 |
| CMML-AML | 9 | 12 |
| t-AML | 27 | 26 |
| Other* | 2 | 2 |
| WBCs, median (range), × 109/L | 3 | 0-156 |
| Hyperleukocytosis | 9 | 9 |
| Cytopenias | 97 | 94 |
| 1 | 25 | 24 |
| 2 | 41 | 40 |
| 3 | 31 | 30 |
| Karyotype | ||
| Complex | 35 | 34 |
| Monosomal | 28 | 27 |
| Prior HMA | 18 | 18 |
| 2017 ELN genetic risk stratification (n = 102) | ||
| Favorable | 2 | 2 |
| Intermediate | 38 | 37 |
| Adverse | 62 | 61 |
| Lindsley’s classifier (n = 80) | ||
| De novo/pan-AML | 21 | 26 |
| Secondary-type mutations AML | 37 | 46 |
| TP53-mutated AML | 22 | 28 |
Values represent n (%) of patients unless otherwise indicated.
Two patients were treated after myeloproliferative neoplasm AML (1 with prior essential thrombocythemia and 1 with myelofibrosis secondary to essential thrombocythemia).